Suppr超能文献

瑞士STAR试验——男性子样本中性传播感染筛查目标群体的评估。

The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of men.

作者信息

Schmidt Axel Jeremias, Rasi Manuela, Esson Cate, Christinet Vanessa, Ritzler Michael, Lung Thomas, Hauser Christoph V, Stöckle Marcel, Jouinot Florent, Lehner Andreas, Lange Katharina, Konrad Torsten, Vernazza Pietro L

机构信息

Division of Infectious Diseases and Infection Control, Cantonal Hospital St Gallen, Switzerland / Communicable Diseases Division, Swiss Federal Office of Public Health, Bern, Switzerland.

Division of Infectious Diseases and Infection Control, Cantonal Hospital St Gallen, Switzerland.

出版信息

Swiss Med Wkly. 2020 Dec 31;150:w20392. doi: 10.4414/smw.2020.20392. eCollection 2020 Dec 14.

Abstract

OBJECTIVES

In Switzerland, universal health insurance does not cover any routine testing for sexually transmitted infections (STIs), not even in individuals at high risk, and extra-genital swabbing is not standard of care. We determined the prevalence and incidence of human immunodeficiency virus (HIV), viral hepatitis and non-viral STIs in a multicentre prospective observational cohort of multi-partner men who have sex with men (MSM) and other men.

MATERIALS AND METHODS

Between January 2016 and June 2017, we offered free STI testing to all men with multiple  sexual partners (three or more in the previous 12 months), with follow-up examinations every 6 months. We used multiplex polymerase chain-reaction testing (for Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Mycoplasma genitalium) on pooled swabs (pharynx, urethra/vagina, anus), and antibody tests for HIV and Treponema pallidum at every visit, and for hepatitis B/C at baseline.

RESULTS

We screened 779 multi-partner MSM and 92 other men. Previously undiagnosed HIV was found in 0.5% vs 0.0%, respectively and T. pallidum antibodies in 15.3% vs 1.1%. STIs requiring antibiotic treatment comprised: active syphilis 1.7% vs 0.0%; N. gonorrhoeae 10.3% vs 0.0%; C. trachomatis 8.7% vs 1.1%. One in four MSM versus 1 in 100 other multi-partner men had any of these three STIs at baseline. 10.4% vs 1.3% had a history of hepatitis B, 31.9% vs 47.3% had no immunity (HBs-AB <10 IU/l). Ten MSM had HCV antibodies (1.4%), with 8 out of the 10 being MSM with HIV; HCV seroprevalence was 0.3% among HIV-negative MSM. In MSM, incidence of the three bacterial STIs was 25.5 per year over 333 person years of follow-up, HIV incidence was 0.3%. Non-condom-use (in the last 3 months) for anal/vaginal sex was not associated with STIs. Independent risk factors were sex with men (adjusted odds ratio [aOR] 16.4) and the number of sexual partners (aOR 2.3 for >20).

CONCLUSION

Among MSM, but not among other multi-partner men, STIs, mostly asymptomatic, are common. Given the high risk of onward transmission, low-cost or free routine screening of multi-partner MSM is a public health priority.

摘要

目的

在瑞士,全民健康保险不涵盖任何性传播感染(STIs)的常规检测,即使是高危个体也不例外,而且生殖器外拭子检查并非标准护理项目。我们在一个多中心前瞻性观察队列中,确定了与多名男性发生性行为的男性(MSM)及其他男性中人类免疫缺陷病毒(HIV)、病毒性肝炎和非病毒性性传播感染的患病率和发病率。

材料与方法

2016年1月至2017年6月期间,我们为所有有多个性伴侣(过去12个月内有三个或更多)的男性提供免费性传播感染检测,并每6个月进行一次随访检查。我们对合并拭子(咽部、尿道/阴道、肛门)进行多重聚合酶链反应检测(用于淋病奈瑟菌、沙眼衣原体、阴道毛滴虫、生殖支原体),每次就诊时进行HIV和梅毒螺旋体抗体检测,基线时进行乙肝/丙肝抗体检测。

结果

我们筛查了779名有多个性伴侣的男男性接触者和92名其他男性。此前未被诊断出的HIV分别在0.5%和0.0%的人群中被发现,梅毒螺旋体抗体分别在15.3%和1.1%的人群中被发现。需要抗生素治疗的性传播感染包括:活动性梅毒1.7%和0.0%;淋病奈瑟菌10.3%和0.0%;沙眼衣原体8.7%和1.1%。四分之一的男男性接触者与百分之一的其他有多个性伴侣的男性在基线时有这三种性传播感染中的任何一种。10.4%和1.3%的人有乙肝病史,31.9%和47.3%的人没有免疫力(乙肝表面抗体<10 IU/l)。10名男男性接触者有丙肝抗体(1.4%),其中10人中有8人是合并感染HIV的男男性接触者;在HIV阴性的男男性接触者中,丙肝血清阳性率为0.3%。在男男性接触者中,在333人年的随访期间,三种细菌性性传播感染的发病率为每年25.5例,HIV发病率为0.3%。肛交/阴道性交时不使用避孕套(过去3个月内)与性传播感染无关。独立危险因素为与男性发生性行为(调整后的优势比[aOR]为16.4)和性伴侣数量(>20个时aOR为

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验